5-year outcomes of a RCT | Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib in patients with BRAF V600–mutant melanoma.

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma – Journal of Clinical Oncology

Editorial: What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma? – Journal of Clinical Oncology